373 related articles for article (PubMed ID: 23340304)
21. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
Nakahata S; Yamazaki S; Nakauchi H; Morishita K
Oncogene; 2010 Jul; 29(29):4157-69. PubMed ID: 20514018
[TBL] [Abstract][Full Text] [Related]
22. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs.
Marudamuthu AS; Shetty SK; Bhandary YP; Karandashova S; Thompson M; Sathish V; Florova G; Hogan TB; Pabelick CM; Prakash YS; Tsukasaki Y; Fu J; Ikebe M; Idell S; Shetty S
J Biol Chem; 2015 Apr; 290(15):9428-41. PubMed ID: 25648892
[TBL] [Abstract][Full Text] [Related]
24. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
25. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
27. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
28. Zeb1 represses Mitf and regulates pigment synthesis, cell proliferation, and epithelial morphology.
Liu Y; Ye F; Li Q; Tamiya S; Darling DS; Kaplan HJ; Dean DC
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5080-8. PubMed ID: 19515996
[TBL] [Abstract][Full Text] [Related]
29. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Pasini FS; Brentani MM; Kowalski LP; Federico MH
Head Neck; 2001 Sep; 23(9):725-32. PubMed ID: 11505481
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Liu G; Shuman MA; Cohen RL
Int J Cancer; 1995 Feb; 60(4):501-6. PubMed ID: 7829264
[TBL] [Abstract][Full Text] [Related]
33. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
34. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
35. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
36. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
37. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1.
Zhang M; Miao F; Huang R; Liu W; Zhao Y; Jiao T; Lu Y; Wu F; Wang X; Wang H; Zhao H; Ju H; Miao S; Wang L; Song W
J Exp Clin Cancer Res; 2018 Feb; 37(1):22. PubMed ID: 29426364
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Dong Z; Saliganan AD; Meng H; Nabha SM; Sabbota AL; Sheng S; Bonfil RD; Cher ML
Neoplasia; 2008 May; 10(5):439-49. PubMed ID: 18472961
[TBL] [Abstract][Full Text] [Related]
39. Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells.
Shetty S; Bdeir K; Cines DB; Idell S
J Biol Chem; 2003 May; 278(20):18124-31. PubMed ID: 12642587
[TBL] [Abstract][Full Text] [Related]
40. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]